Johnson & Johnson (BKK:JNJ03)
Thailand · Delayed Price · Currency is THB | Market Cap | 17.66T +41.1% |
| Revenue (ttm) | 3.17T +7.9% |
| Net Income | 691.44B -3.5% |
| EPS | 283.78 -3.9% |
| Shares Out | n/a |
| PE Ratio | 25.54 |
| Forward PE | 18.92 |
| Dividend | 0.03 (0.89%) |
| Ex-Dividend Date | Feb 24, 2026 |
| Volume | 74,715 |
| Average Volume | 116,685 |
| Open | 3.740 |
| Previous Close | n/a |
| Day's Range | 3.680 - 3.760 |
| 52-Week Range | 2.980 - 4.060 |
| Beta | n/a |
| RSI | 39.23 |
| Earnings Date | Apr 14, 2026 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription... [Read more]
Financial Performance
In 2025, Johnson & Johnson's revenue was $94.19 billion, an increase of 6.05% compared to the previous year's $88.82 billion. Earnings were $26.80 billion, an increase of 90.56%.
Financial numbers in USD Financial StatementsNews
CVS to drop J&J's Stelara from its main formularies
CVS Health said on Tuesday it would prefer lower-cost, interchangeable biosimilars over Johnson & Johnson's psoriasis drug Stelara in its most common drug lists starting July 1.
Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease
TREMFYA ® demonstrated significantly higher rates of combined fistula remission – complete external closure of draining fistulas and absence of fluid collection on MRI – compared to placebo at Week 24...
Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease
JNJ-4804 demonstrated highest rates of clinical and endoscopic outcomes compared to golimumab and guselkumab in patients with ulcerative colitis or Crohn's disease who have had inadequate response to ...
Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System
SANTA CLARA, Calif.--(BUSINESS WIRE)--Johnson & Johnson announces results from the first clinical study of the investigational OTTAVA™ Robotic Surgical System.
CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis
CAPLYTA ® ranked highest among FDA-approved adjunctive therapies across four measures of efficacy, based on indirect comparisons from placebo plus antidepressant therapy-controlled trials Among the se...
J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine
Spravato, the ketamine-derived nasal spray from Johnson & Johnson, was once seen as a long shot. It was difficult to deliver, heavily regulated and slow to catch on.
Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”) today announced the appointment of Ryan Koors to Vice President, Investor Relations, effective May 7, 2026. Mr. Koor...
Why These 3 Forever Stocks Belong on Your Watchlist
These companies have proved to be good stocks to buy and hold for the long term.
Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Bernstein's 42nd Annual Strategic Decisions Conference on Wednesday, May 27th, 2026. Management will participate...
J&J sees AI halving the time to generate drug development leads
Johnson & Johnson is using artificial intelligence to slash by half the time it takes to generate new leads for developing drugs, the company's chief information officer said on Monday.
FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)
Priority Review is granted to medicines that may offer significant improvements in safety or effectiveness for serious conditions like warm autoimmune hemolytic anemia, a life-threatening disease in w...
Johnson & Johnson to launch on TrumpRx with four of its prescription drugs, CBS News reports
Johnson & Johnson will start marketing four of its medications on the Trump administration's TrumpRx website on Friday, CBS News reported on Friday.
Cramer says look to these 4 stocks to go with your high-flying tech names
CNBC's Jim Cramer urged investors to look at parts of the market that have already been beaten down. He highlighted four stocks in the health-care sector as alternatives to high-flying technology and ...
Johnson & Johnson Transcript: AGM 2026
Strong financial growth in 2025 included a 43% share price increase and record pharmaceutical sales. All board nominees and management proposals passed, while a shareholder proposal was rejected. Strategic focus remains on innovation, portfolio strength, and disciplined capital allocation.
IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)
Through 120 weeks of follow-up, IMAAVY delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+ Patients achieving ...
Johnson & Johnson Announces CE Mark Approval for the New ETHICON™ 4000 Stapler
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson announces that it has received European CE Mark approval for its new ETHICON™ 4000 Stapler.
Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19th. Management will participate in a...
Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026
IRVINE, Calif.--(BUSINESS WIRE)--Johnson & Johnson showcases CARTO-powered innovation, including debut of CARTOSOUND SONATA, to advance arrhythmia care at HRS 2026.
US judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims
A U.S. judge has rejected Bayer's request for an injunction to block Johnson & Johnson's alleged false advertising that its multibillion-dollar drug cuts the risk of death from prostate cancer in hal...
U.S. judge rejects Bayer's bid to block Johnson & Johnson prostate cancer drug claims
A federal judge rejected Bayer's request for an injunction to block Johnson & Johnson's alleged false advertising that its multibillion-dollar drug cuts the risk of death from prostate cancer i...
Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson
XLRP is a severe, progressive genetic eye disease causing early-onset night blindness and peripheral vision loss, leading to legal blindness by age 40–45.
Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Bank of America 2026 Healthcare Conference on Tuesday, May 12th, 2026. Management will participate in a Fireside...
These Analysts Boost Their Forecasts On Johnson & Johnson Following Strong Q1 Results
Johnson & Johnson (NYSE: JNJ) on Tuesday posted upbeat earnings for the first quarter.
Johnson & Johnson Posts Solid Q1 To Kickstart 'Year Of Accelerating Growth,' Says Bullish Analyst
• Johnson & Johnson stock is trending lower. Why is JNJ stock trading lower?
Johnson & Johnson CFO on the company's robotic surgical system
Johnson & Johnson CFO Joseph Wolk discusses the company's latest FDA application for its OTTAVA robotic surgical system.